Oncology Brothers: Practice-Changing Cancer Discussions
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Listen on:
Episodes
Thursday Sep 25, 2025
Thursday Sep 25, 2025
In this episode of the Oncology Brothers podcast, we are joined by Dr. Omid Hamid, a melanoma specialist from Cedars-Sinai, to explore the current treatment landscape of cutaneous melanoma.
We covered a wide range of topics, including:• The standard of care for early-stage melanoma, including wide local excision and sentinel lymph node evaluation.• The role of adjuvant immunotherapy and BRAF/MEK inhibitors for high-risk patients.• Insights into neoadjuvant treatment options for resectable disease, including recent trial data from NADINA and SWOG S1808.• The importance of next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) in treatment planning and monitoring.• The evolving treatment paradigm for metastatic melanoma, including the use of dual checkpoint inhibitors and BRAF/MEK inhibitors.
Join us as we discuss the latest advancements in melanoma treatment and the critical role of patient education and shared decision-making in oncology care.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes on treatment algorithms, new FDA approvals, and conference highlights!
#Melanoma #Immunotherapy #BRAF #ctDNA #Neoadjuvant #OncologyBrothers
Monday Sep 22, 2025
Monday Sep 22, 2025
Welcome to the Oncology Brothers podcast! In this episode, we dive deep into the world of neuroendocrine tumors (NETs) with renowned expert Dr. Thor Halfdanarson from the Mayo Clinic.
Join us as we explore:• The critical factors in diagnosing NETs, including origin, grade, histological features, and Ki-67.• The importance of differentiating between functional and non-functional tumors and how this impacts treatment decisions.• Dr. Halfdanarson's treatment paradigm, including the use of somatostatin analogs, radioligand therapy, and other targeted treatments.• Monitoring strategies for patients, including the role of imaging and tumor markers like 5-HIAA and chromogranin.• Insights into the evolving role of immunotherapy and next-generation sequencing in managing high-grade neuroendocrine carcinomas.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable information and practical insights.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to subscribe for more discussions on cutting-edge cancer treatments and expert opinions in the field of oncology!
Thursday Sep 18, 2025
Thursday Sep 18, 2025
Join us in this episode of the Oncology Brothers podcast as we dive into the highlights from the World Conference on Lung Cancer 2025! We are joined by Dr. Balazs Halmos, a thoracic medical oncologist at the Montefiore Einstein Cancer Center, to discuss three pivotal studies that are shaping the future of lung cancer treatment.
In this episode, we covered:• FLAURA2 Trial: Discover the significant overall survival benefits of combining osimertinib with chemotherapy for patients with EGFR-positive non-small cell lung cancer, and how it compares to single-agent osimertinib.• HARMONi Trial: Explore the intriguing yet complex findings of a new bi-specific antibody targeting PD-1 and VEGF in patients with progressive EGFR-mutated disease, and the implications of its current negative results.• ALCHEMIST Trial: Learn about the role of crizotinib in the adjuvant setting for ALK-positive lung cancer and why it reinforces alectinib as the standard of care.
Tune in for an insightful discussion on the latest advancements in precision medicine, the importance of ctDNA, and the evolving landscape of lung cancer treatment.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Thursday Sep 11, 2025
Thursday Sep 11, 2025
Join us for an insightful episode as we dive deep into the evolving landscape of Chronic Lymphocytic Leukemia (CLL) treatment. This episode features Dr. Mazyar Shadman, an expert in lymphoid malignancies from the Fred Hutch Cancer Center.
In this episode, we covered:• The importance of shared decision-making in CLL treatment.• When to initiate treatment for newly diagnosed CLL patients.• The role of time-limited venetoclax-based regimens versus continuous BTK inhibitors.• Key considerations in choosing the right BTK inhibitor and managing side effects.• The relevance of minimal residual disease (MRD) in treatment duration.• Sequencing strategies for relapsed and refractory CLL, including the use of Pirtobrutinib and CAR-T therapy.
Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode is packed with valuable insights and practical advice.
Don't forget to like, subscribe, and leave us your feedback! Your support helps us bring these important discussions to a wider audience. Tune in now and stay informed about the latest in CLL treatment!
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
#Ibrutinib #acalabrutinib #zanubrutinib #Pirtobrutinib #CLL2025 #BTKinhibitors #Venetoclax #MRDnegative #OncologyBrothers
Friday Aug 29, 2025
Friday Aug 29, 2025
Welcome back to the Oncology Brothers podcast! In this episode, we continue the three-part CME series on small cell lung cancer, focusing on adverse events and management strategies for extensive stage small cell lung cancer treatments.
We are thrilled to have Dr. Misty Shields from the Indiana University join us to discuss the latest advancements in treatment options following the exciting data presented at ASCO 2025. We dived into the treatment algorithm for patients with good performance status, including the use of chemoimmunotherapy, lurbinectedin, and tarlatamab.
Key topics covered in this episode:• Overview of the current treatment landscape and new data from ASCO 2025• Common side effects associated with lurbinectedin and immunotherapy• Strategies for managing adverse events, including hematologic toxicities and liver function monitoring• The role of supportive care and palliative care in enhancing patient quality of life• Collaboration between community oncologists and academic centers for optimal patient care
Join us as we explore the challenges and opportunities in managing extensive stage small cell lung cancer, and learn how to provide the best care for patients facing this devastating disease.
Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:https://www.gotoper.com/courses/practical-considerations-and-future-directions-for-new-treatment-strategies-in-sclc
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
#SCLCtoxicity #Lurbinectedin #Tarlatamab #SupportiveOncology #CMEoncology
Monday Aug 25, 2025
Monday Aug 25, 2025
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rohit & Rahul Gosain are joined by Dr. Joshua Sabari from the NYU Langone Cancer Center to discuss the exciting recent approval of Zongertinib, the first oral TKI for HER2-positive lung cancer.
We dived deep into the prevalence of HER2 mutations in non-small cell lung cancer, the study design and findings from the Beamion LUNG-1 trial, and the implications of this new therapy in clinical practice. Dr. Sabari shared insights on the efficacy of Zongertinib, including impressive response rates and progression-free survival data, as well as its side effect profile compared to other treatments like trastuzumab deruxtecan (T-DXd).
Key topics covered in this episode:• Overview of HER2 mutations in lung cancer• Study design and results of the Beamion LUNG-1• Comparison of Zongertinib and T-DXd in treatment settings• Management of common side effects associated with Zongertinib• Future directions for HER2-targeted therapies
Join us for this informative discussion as we explore the latest advancements in lung cancer treatment and what they mean for patients and clinicians alike. Don't forget to subscribe for more episodes on new approvals, side effect management, and practice-changing data in oncology!
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Thursday Aug 21, 2025
Thursday Aug 21, 2025
Welcome to the Oncology Brothers podcast! In this episode, we kick off a three-part CME series focused on small cell lung cancer (SCLC). Joined by Dr. Hossein Borghaei, Chief of Thoracic Oncology at the Fox Chase Cancer Center. Together they dived into the evolving treatment landscape for SCLC, highlighting recent advancements and data from ASCO 2025.
Episode Highlights:• Overview of the current standard of care for limited and extensive-stage SCLC.• Discussion on the role of concurrent chemoradiation therapy and the new standard of care involving immunotherapy.• Insights into the use of lurbinectedin in maintenance therapy and its impact on overall survival.• Exploration of the promising results from the DeLLphi study on tarlatamab, a bispecific antibody, and its implications for treatment.• The importance of patient selection and managing side effects in treatment decisions.
Join us as we navigate the complexities of SCLC treatment and look forward to future advancements that may improve patient outcomes.
Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial SupportThis activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:https://www.gotoper.com/courses/breaking-down-the-latest-clinical-data-for-first-line-maintenance-and-rr-sclc
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
#OncologyBrothers #SmallCellLungCancer #CME #ASCO2025 #LungCancer #Immunotherapy #CancerTreatment
Monday Aug 18, 2025
Monday Aug 18, 2025
In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain welcome Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, to discuss the recent FDA approval of Dato-DXD (datopotamab deruxtecan) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC).
Key Topics:• Overview of Dato-DXd and its FDA approval• Mechanism of action and study design of the TROPION Lung trials• Efficacy and safety profile of Dato-DXd• Management of side effects and clinical pearls• Treatment sequencing for EGFR-mutated NSCLC
Join us as we dive into the details of the TROPION Lung trials that led to this significant approval, the mechanism of action of Dato-DXd, and the implications for patients with various EGFR mutations. Dr. Sands shared insights on the study design, efficacy, and tolerability of this new antibody-drug conjugate, as well as important clinical pearls for managing side effects such as stomatitis, dry eyes, and interstitial lung disease (ILD).We also explored the current treatment landscape for EGFR-mutated NSCLC, including the sequencing of therapies and the potential role of Dato-DXd in clinical practice.Tune in for an informative discussion that highlights the exciting advancements in oncology and the hope they bring to patients.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!
Monday Aug 11, 2025
Monday Aug 11, 2025
Welcome to the Oncology Brothers podcast! In this episode, we continue our hematology series by diving deep into myelofibrosis (MF) with Dr. Raajit Rampal, an expert in myeloproliferative neoplasms from the Memorial Sloan Kettering Cancer Center.
Join Drs. Rahul and Rohit Gosain as they discuss the latest updates in symptom management, emerging treatment combinations, and the importance of timely diagnosis and risk stratification for patients presenting with cytopenias and splenomegaly.
Key topics covered in this episode include:• The initial workup and diagnostic criteria for myelofibrosis• The role of next-generation sequencing and bone marrow biopsy• Risk stratification using the IPSS and DIPSS scoring systems• First-line treatment options, including the four available JAK inhibitors: Ruxolitinib, Momelotinib, Fedratinib, and Pacritinib• Supportive care strategies for managing anemia and thrombocytopenia• The importance of clinical trials and early referral for transplant
Tune in to gain valuable insights into the evolving treatment landscape for myelofibrosis and learn how community oncologists can effectively manage this complex disease.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes in our hematology series and check out our previous discussions!
Thursday Aug 07, 2025
Thursday Aug 07, 2025
Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by world-renowned medical oncologist Dr. Monty Pal from the City of Hope. Together, they dived deep into the management of side effects associated with tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors used in treating renal cell carcinoma (RCC).
Episode Highlights:• Understanding TKIs and HIF-2 Inhibitors: A discussion on the available oral treatment options for RCC, including cabozantinib, lenvatinib, and axitinib.• Dosing Strategies: Insights on starting doses, titration, and the importance of managing side effects without compromising quality of life.• Common Side Effects: hypertension, diarrhea, fatigue, and how they relate to the class effect of these medications.• Clinical Pearls: Dr. Pal shared valuable tips on managing toxicities, including the use of treatment breaks and supportive care strategies.• Second-Line Treatments: A look at tivozanib and belzutifan, including their unique side effects and management strategies.
Join us as we emphasized the importance of maintaining quality of life for patients undergoing treatment for metastatic RCC.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to check out our other episodes for more insights on treatment algorithms, conference highlights, and challenging cases from the community.